Oculus Innovative Sciences Announces Preliminary Results From 40-Patient Feasibility Study For Treatment Of Acne With The Microcyn(R) Technology

Main Category: Dermatology
Article Date: 22 Jun 2009 - 4:00 PDT

email to a friend   printer friendly   view / write opinions   rate article

Oculus Innovative Sciences, Inc. (Nasdaq: OCLS), a healthcare company that develops, manufactures and markets a family of products based upon the Microcyn® Technology platform, announced that preliminary results from its U.S. 40-patient feasibility study, in which an enhanced formulation of the company's Microcyn Technology-based hydrogel was used in the treatment of acne, are highly encouraging and warrant further examination.

"In the treatment of acne, we have observed preliminary results which suggest that this hydrogel formulation may reduce the need for laser treatment and chemical peels to address skin damage caused by acne or acne treatments," said Cheryl Bongiovanni, director of the Lakes Aesthetics Center in Lakeview, Oregon. "The promising preliminary results, including elimination of secondary infection and inflammation and reduction of new scarring, warrant further research of the possible long-term impact of this formulation to determine whether the effects are sustainable."

The company plans to utilize this information to evaluate the potential of near-term market opportunities while exploring longer-term partnerships with a number of prospective companies.

During its Q4 2009 earnings call this past week, Oculus provided specific guidance regarding the company's potential revenue in fiscal year 2013 as well as its targeted cash breakeven in March 2010. In light of the new acne data and the potential upsides, Oculus management intends to discuss the revenue impact of this new market opportunity during its Q1 2010 earnings call in August.

Source
Oculus Innovative Sciences